Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
The global celiac disease market is witnessing significant growth, fueled by rising awareness of gluten-related disorders, increasing prevalence of celiac disease, and advancements in diagnostic and therapeutic options. Celiac disease affects millions worldwide, with growing diagnosis rates particularly in the U.S., Europe, and Asia-Pacific regions. The global celiac disease market is evolving as pharmaceutical companies and food manufacturers focus on developing effective treatment modalities and gluten-free product offerings to meet patient needs. The celiac disease market is driven by the expanding adoption of gluten-free diets, emerging pharmacological therapies, and improvements in diagnostic technologies that enable early and accurate detection. Increased healthcare expenditure and improved patient education in key markets such as the U.S., U.K., and Germany contribute substantially to the market's upward trajectory. Moreover, growing clinical research on novel drug candida
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Takeda Pharmaceutical (TAK) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
- Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Takeda plans to lay off 400 employees in US - report [Seeking Alpha]Seeking Alpha
- Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia VeraBusiness Wire
- Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative ColitisBusiness Wire
TAK
Sec Filings
- 3/2/26 - Form 6-K
- 2/10/26 - Form 6-K
- 1/29/26 - Form 6-K
- TAK's page on the SEC website